Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
36.42 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Harmony Biosciences Holdings, Inc. |
Symbool | HRMY |
Munteenheid | USD |
Prijs | 36.42 |
Beurswaarde | 2,077,079,946 |
Dividendpercentage | 0% |
52-weken bereik | 28.14 - 41.61 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jeffrey M. Dayno M.D. |
Website | https://www.harmonybiosciences.com |
An error occurred while fetching data.
Over Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)